Technology
Health
Medical

Pulse Biosciences

$12.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PLSE and other stocks, options, ETFs, and crypto commission-free!

About

Pulse Biosciences, Inc Common Stock (DE), also called Pulse Biosciences, is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary Nano-Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. Read More The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Employees
54
Headquarters
Hayward, California
Founded
2014
Market Cap
258.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
66.92K
High Today
$12.86
Low Today
$12.22
Open Price
$12.34
Volume
6.51K
52 Week High
$19.77
52 Week Low
$8.60

Collections

Technology
Health
Medical
Energy
2016 IPO
US
North America

News

Seeking AlphaApr 30

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2019 Results - Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Vice President and General Manager-Dermatology Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen and welcome to the Pulse Biosciences First Quarter 2019 Investor and Analyst Call. At this time, all ...

1,117
Yahoo FinanceApr 30

Pulse Biosciences Quarterly Investor Conference Call

HAYWARD, Calif.--(BUSINESS WIRE)-- Conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT Pulse Biosciences, Inc. (PLSE) (the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, today reported recent corporate developments and financial results for the quarter ended March 31, 2019. Recent Corporate Developments Pre-market Notification (510(k)) submitted to the U.S. Food and Drug Administration (FDA) for its proprietary CellFX System seeking clearance for c...

139

Earnings

-$0.64
-$0.57
-$0.51
-$0.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.